Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) reported a quarterly loss of $0.14 per share, missing analyst expectations by $0.02, despite revenue of $0.10 million surpassing the consensus estimate. The company's shares are trading under pressure, well below moving averages, and analysts generally hold a "Hold" rating. Despite some insider buying, institutional ownership stands at 16.29%, as the clinical-stage biotech continues its work on small-molecule immuno-oncology therapies.